The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms
Open accessAbstract
The p53 transcription factor is a potent suppressor of tumor growth. We report here an analysis of its direct transcriptional program using Global Run-On sequencing (GRO-seq). Shortly after MDM2 inhibition by Nutlin-3, low levels of p53 rapidly activate ∼200 genes, most of them not previously established as direct targets. This immediate response involves all canonical p53 effector pathways, including apoptosis. Comparative global analysis of RNA synthesis vs steady state levels revealed that microarray profiling fails to identify low abundance transcripts directly activated by p53. Interestingly, p53 represses a subset of its activation targets before MDM2 inhibition. GRO-seq uncovered a plethora of gene-specific regulatory features affecting key survival and apoptotic genes within the p53 network. p53 regulates hundreds of enhancer-derived RNAs. Strikingly, direct p53 targets harbor pre-activated enhancers highly transcribed in p53 null cells. Altogether, these results enable the study of many uncharacterized p53 target genes and unexpected regulatory mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 2×
“DOI: 10.7554/eLife.02200 2 of 29 Research article required for binding to p53, thus acting as a competitive inhibitor (Vassilev et al., 2004).”
BackgroundInfluentialRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 4×
“…that MDM2 represses p53 by both masking its transactivation domain and also targeting it for degradation (Momand et al., 1992; Oliner et al., 1993; Kubbutat et al., 1997), it has been difficult to dissect to what extent each mechanism contributes to repression of p53 target genes in diverse…”
BackgroundInfluentialBlinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 3×
“Although it is known that MDM2 represses p53 by both masking its transactivation domain and also targeting it for degradation (Momand et al., 1992; Oliner et al., 1993; Kubbutat et al., 1997), it has been difficult to dissect to what extent each mechanism contributes to repression of p53 target…”
BackgroundA model for p53-induced apoptosis
Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/38525 · Cited by 2,500
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Self-citationTranscriptional control of human p53-regulated genes
Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921
A high-resolution map of the three-dimensional chromatin interactome in human cells
Jin, F., Li, Y., Dixon, J. R., Selvaraj, S., Ye, Z., Lee, A. Y., Yen, C.-A., Schmitt, A. D., Espinoza, C. A., & Ren, B. (2013) · Nature · doi:10.1038/nature12644 · Cited by 1,208
A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome
Wei, C.-L., Wu, Q., Vega, V. B., Chiu, K. P., Ng, P., Zhang, T., Shahab, A., Yong, H. C., Fu, Y., Weng, Z., et al. (2006) · Cell · doi:10.1016/j.cell.2005.10.043 · Cited by 1,141 · cited 2×
“Meta-analysis of published p53 ChIP-seq data To create a list of high confidence p53 binding sites, we combined the data from of 7 ChIP assays for p53 (Wei et al., 2006; Smeenk et al., 2008; Smeenk et al., 2011; Nikulenkov et al., 2012) and kept only sites that were found in at least five of the seven assays.”
MethodAwakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881 · cited 2×
“Significant advances have been made to develop p53-based targeted therapies (Brown et al., 2009).”
BackgroundChen, X., Ko, L. J., Jayaraman, L., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.19.2438 · Cited by 735
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
eRNAs Are Required for p53-Dependent Enhancer Activity and Gene Transcription
Melo, C. A., Drost, J., Wijchers, P. J., van de Werken, H., de Wit, E., Vrielink, J. A. F. O., Elkon, R., Melo, S. A., Léveillé, N., Kalluri, R., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.11.021 · Cited by 544
Repression of p53-mediated transcription by MDM2: a dual mechanism
Thut, C. J., Goodrich, J. A., & Tjian, R. (1997) · Genes & Development · doi:10.1101/gad.11.15.1974 · Cited by 272
Li, M., He, Y., Dubois, W., Wu, X., Shi, J., & Huang, J. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.01.020 · Cited by 264
Espinosa, J. M., Verdun, R. E., & Emerson, B. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00359-9 · Cited by 256
Self-citationCharacterization of genome-wide p53-binding sites upon stress response
Smeenk, L., van Heeringen, S. J., Koeppel, M., van Driel, M. A., Bartels, S. J. J., Akkers, R. C., Denissov, S., Stunnenberg, H. G., & Lohrum, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn232 · Cited by 211
Menendez, D., Nguyen, T.-A., Freudenberg, J. M., Mathew, V. J., Anderson, C. W., Jothi, R., & Resnick, M. A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt504 · Cited by 154 · cited 11×
“Since then, genomics experiments using microarrays and ChIP-seq suggest thousands of p53 targets, but very few genes were commonly identified by multiple studies (Figure 2—figure supplement 1A,B) (Nikulenkov et al., 2012; Menendez et al., 2013; Schlereth et al., 2013; Wang et al., 2013).”
BackgroundMethodInfluentialSchlereth, K., Heyl, C., Krampitz, A.-M., Mernberger, M., Finkernagel, F., Scharfe, M., Jarek, M., Leich, E., Rosenwald, A., & Stiewe, T. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003726 · Cited by 87
Regulation of the p53 transcriptional response by structurally diverse core promoters
Morachis, J. M., Murawsky, C. M., & Emerson, B. M. (2010) · Genes & Development · doi:10.1101/gad.1856710 · Cited by 86
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53
Sullivan, K. D., Padilla-Just, N., Henry, R. E., Porter, C. C., Kim, J., Tentler, J. J., Eckhardt, S. G., Tan, A. C., DeGregori, J., & Espinosa, J. M. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.965 · Cited by 67
Self-citation
Research works printed but not linked: 30
- Anders, 2010, Differential expression analysis for sequence count data, Genome Biology, 11, R106, 10.1186/gb-2010-11-10-r106 · DOI · Paper page
- Andrysik, 2013, A genetic screen identifies TCF3/E2A and TRIAP1 as pathway-specific regulators of the cellular response to p53 activation, Cell Reports, 3, 1, 10.1016/j.celrep.2013.04.014 · DOI
- Benson, 2013, p53-dependent gene repression through p21 is mediated by recruitment of E2F4 repression complexes, Oncogene, 10.1038/onc.2013.378 · DOI · Paper page
- Biderman, 2012, Mdm2 and MdmX as regulators of gene expression, Genes & cancer, 3, 264, 10.1177/1947601912455331 · DOI
- Cohen, 1998, Characterization of a new intrabody directed against the N-terminal region of human p53, Oncogene, 17, 2445, 10.1038/sj.onc.1202190 · DOI
- Core, 2008, Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters, Science, 322, 1845, 10.1126/science.1162228 · DOI · Paper page
- Das, 2007, Hzf Determines cell survival upon genotoxic stress by modulating p53 transactivation, Cell, 130, 624, 10.1016/j.cell.2007.06.013 · DOI · Paper page
- Espinosa, 2001, Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment, Molecular Cell, 8, 57, 10.1016/S1097-2765(01)00283-0 · DOI · Paper page
- Gomes, 2006, Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program, Genes & Development, 20, 601, 10.1101/gad.1398206 · DOI · Paper page
- Hah, 2011, A rapid, extensive, and transient transcriptional response to estrogen signaling in breast cancer cells, Cell, 145, 622, 10.1016/j.cell.2011.03.042 · DOI · Paper page
- Hargreaves, 2009, Control of inducible gene expression by signal-dependent transcriptional elongation, Cell, 138, 129, 10.1016/j.cell.2009.05.047 · DOI · Paper page
- Henry, 2012, A DR4:tBID axis drives the p53 apoptotic response by promoting oligomerization of poised BAX, The EMBO Journal, 31, 1266, 10.1038/emboj.2011.498 · DOI
- Ivshina, 2006, Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer, Cancer Research, 66, 10292, 10.1158/0008-5472.CAN-05-4414 · DOI · Paper page
- Jiao, 2013, RNA-mediated gene activation, Epigenetics, 9, 27, 10.4161/epi.26942 · DOI
- Lal, 2011, Capture of microRNA-bound mRNAs identifies the tumor suppressor miR-34a as a regulator of growth factor signaling, PLOS Genetics, 7, e1002363, 10.1371/journal.pgen.1002363 · DOI · Paper page
- Laptenko, 2006, Transcriptional regulation by p53: one protein, many possibilities, Cell Death and Differentiation, 13, 951, 10.1038/sj.cdd.4401916 · DOI · Paper page
- Lowe, 1994, p53 status and the efficacy of cancer therapy in vivo, Science, 266, 807, 10.1126/science.7973635 · DOI · Paper page
- Nikulenkov, 2012, Insights into p53 transcriptional function via genome-wide chromatin occupancy and gene expression analysis, Cell Death and Differentiation, 19, 1992, 10.1038/cdd.2012.89 · DOI · Paper page
- Ohkubo, 2006, Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription, The Journal of Biological Chemistry, 281, 16943, 10.1074/jbc.M601388200 · DOI
- Oliner, 1993, Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53, Nature, 362, 857, 10.1038/362857a0 · DOI · Paper page
- Picksley, 1994, Immunochemical analysis of the interaction of p53 with MDM2;–fine mapping of the MDM2 binding site on p53 using synthetic peptides, Oncogene, 9, 2523
- Poyurovsky, 2010, The C terminus of p53 binds the N-terminal domain of MDM2, Nature Structural & Molecular Biology, 17, 982, 10.1038/nsmb.1872 · DOI
- Riemenschneider, 1999, Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification, Cancer Research, 59, 6091
- Smeenk, 2011, Role of p53 serine 46 in p53 target gene regulation, PLOS ONE, 6, e17574, 10.1371/journal.pone.0017574 · DOI · Paper page
- Szak, 2001, Kinetics of p53 binding to promoter sites in vivo, Molecular and Cellular Biology, 21, 3375, 10.1128/MCB.21.10.3375-3386.2001 · DOI · Paper page
- Tang, 1998, Constitutive expression of the cyclin-dependent kinase inhibitor p21 is transcriptionally regulated by the tumor suppressor protein p53, The Journal of Biological Chemistry, 273, 29156, 10.1074/jbc.273.44.29156 · DOI
- Wang, 2013, Mapping the p53 transcriptome universe using p53 natural polymorphs, Cell Death and Differentiation, 21, 521, 10.1038/cdd.2013.132 · DOI
- White, 2006, Mouse double minute 2 associates with chromatin in the presence of p53 and is released to facilitate activation of transcription, Cancer Research, 66, 3463, 10.1158/0008-5472.CAN-05-1381 · DOI
- Yan, 2007, BLIMP1 regulates cell growth through repression of p53 transcription, Proceedings of the National Academy of Sciences of the United States of America, 104, 1841, 10.1073/pnas.0605562104 · DOI
- Zhao, 2000, Analysis of p53-regulated gene expression patterns using oligonucleotide arrays, Genes & Development, 14, 981, 10.1101/gad.827700 · DOI · Paper page
Cited by
Functional Classification and Experimental Dissection of Long Noncoding RNAs
Kopp, F., & Mendell, J. T. (2018) · Cell · doi:10.1016/j.cell.2018.01.011 · Cited by 3,529
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Cao, J. Y., & Dixon, S. J. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2194-1 · Cited by 1,515
“…p53-dependent effects on SLC7A11 -mediated Cys 2 uptake fit within this emerging picture of p53-dependent metabolic modulation, although it should be noted that SLC7A11 was not identified in other comprehensive studies of genomic p53 binding sites and direct p53 transcriptional targets [71, 72].”
BackgroundHow does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression
Aubrey, B. J., Kelly, G. L., Janic, A., Herold, M. J., & Strasser, A. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.169 · Cited by 1,395
The multiple mechanisms that regulate p53 activity and cell fate
Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0110-x · Cited by 1,129
Metadata
- Authors
- Allen, M. A., Andrysik, Z., Dengler, V. L., Mellert, H. S., Guarnieri, A., Freeman, J. A., Sullivan, K. D., Galbraith, M. D., Luo, X., Kraus, W. L., Dowell, R. D., & Espinosa, J. M.
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2014-05-27
- Volume
- 3
- Pages
- e02200-e02200
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W1981974167
- Cited by
- 238
- References
- 22
- FWCI
- 11.35
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/3.0/ (vor)
- creativecommons.org/licenses/by/3.0/ (am)
- creativecommons.org/licenses/by/3.0/ (tdm)
- Funders
- Howard Hughes Medical Institute (Early Career Award)
- National Institutes of Health (RO1 CA117907-07, 2T15 LM009451)
- Butcher Foundation
- Boettcher Foundation
- National Science Foundation (MCB1243522)
- American Cancer Society
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.